<DOC>
	<DOCNO>NCT00785395</DOCNO>
	<brief_summary>This study design determine minimum effective dose ( ED90 ) infusion oxytocin prevention uterine atony / postpartum hemorrhage need additional uterotonics , low risk parturients present elective CD . The primary outcome measure response effective uterine contraction either satisfactory unsatisfactory determine obstetrician blind oxytocin infusion dose . Secondary outcome include need additional uterotonics , calculate intra-operative blood loss presence oxytocin related adverse effect .</brief_summary>
	<brief_title>Up-Down Oxytocin Infusion</brief_title>
	<detailed_description />
	<mesh_term>Uterine Inertia</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Nonemergent cesarean delivery plan spinal anesthesia ( i.e . elective planned cesarean delivery malposition , patient choice , cervical pelvic disproportion , previous cesarean delivery diagnosis require predetermine cesarean delivery ) 2 . American Society Anesthesia physical status class I &amp; II ( ASA I Healthy , ASA II mild control systemic disease , eg . control essential hypertension ) 3 . Age ≥ 18 year 4 . Term gestational age ( ≥ 37 week ) 5 . Englishspeaking 1 . Morbid Obesity ( Body Mass Index ≥ 45 kg/m2 ) ( Morbidly obese parturients require dose local anesthetic less standardized dose study blood pressure cuff occasionally need replaced intraarterial catheter due limitation size ) 2 . Laboring woman 3 . Urgent emergency cesarean delivery 4 . Severe hypertensive disease pregnancy define systolic blood pressure ( SBP ) &gt; 160mmHg , diastolic blood pressure ( DBP ) &gt; 110mmHg and/or require antihypertensive treatment associate significant proteinuria 5 . Severe maternal cardiac disease 6 . Subjects predispose uterine atony postpartum hemorrhage ( i.e . placenta previa , multiple gestation , macrosomia , polyhydramnios , uterine abnormality , bleed diathesis , &gt; 2 previous CD ) 7 . Fetal anomaly /Intrauterine Fetal Demise 8 . Failed spinal anesthesia 9 . Patient enrollment another study involve study medication within 30 day CD 10 . Any physical psychiatric condition may impair ability cooperate study data collection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>